Form 4: Verve Therapeutics Chief Scientific Officer Troy Lister Reports Stock Transactions
SEC Form 4
Troy Lister, Chief Scientific Officer of Verve Therapeutics, reports the vesting and sale of common stock to cover tax obligations.
Summary
- On April 1, 2025, Troy Lister, Chief Scientific Officer of Verve Therapeutics, settled 7,340 restricted stock units (RSUs) into common stock.
- On April 2, 2025, Lister sold 2,189 shares of common stock at $4.15 per share.
- The sale was executed automatically under a pre-arranged plan to cover withholding tax liabilities from the vesting of RSUs.
- Following these transactions, Lister directly owns 6,952 shares of Verve Therapeutics common stock and 18,705 restricted stock units.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reflects routine transactions related to executive compensation. There is no indication of positive or negative news regarding the company's performance.
Positives
- The transactions are part of a pre-arranged plan, indicating no discretionary trading based on insider information.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency regarding insider transactions.
Comparison to Industry Standards
- Executive compensation packages often include restricted stock units that vest over time.
- Sales of stock to cover tax obligations upon vesting are a common practice among executives at publicly traded companies.
- The use of pre-arranged trading plans (Rule 10b5-1) is a standard method to avoid accusations of insider trading.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are part of a pre-arranged plan and do not represent a significant change in ownership.
Key Dates
| Date | Description |
|---|---|
| March 20, 2023 | Date of adoption of durable automatic sale instruction plan. |
| February 14, 2023 | Grant date of 13,260 RSUs, vesting starting April 1, 2024. |
| February 14, 2024 | Grant date of 16,100 RSUs, vesting starting April 1, 2025. |
| April 1, 2024 | First vesting date for RSUs granted on February 14, 2023. |
| April 1, 2025 | Settlement of 7,340 RSUs into common stock and first vesting date for RSUs granted on February 14, 2024. |
| April 2, 2025 | Sale of 2,189 shares of common stock at $4.15 per share. |
| April 3, 2025 | Date of Form 4 filing. |
| April 1, 2027 | Final vesting date for RSUs granted on February 14, 2023. |
| April 1, 2028 | Final vesting date for RSUs granted on February 14, 2024. |
Keywords
Verve Therapeutics, Troy Lister, Chief Scientific Officer, Form 4, Stock, RSU, Restricted Stock Units, Beneficial Ownership, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.